Using the neutrophil‐to‐lymphocyte ratio to predict the outcome of individuals with nonsquamous non‐small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed

BACKGROUND: Factors predicting the response to pembrolizumab plus platinum and pemetrexed combination therapy (Pemb‐Plt‐PEM) in nonsquamous non‐small cell lung cancer (non‐sq NSCLC) are unclear. We investigated the Glasgow Prognostic (GP) score, neutrophil‐to‐lymphocyte ratio (NLR), and body mass in...

Descripción completa

Detalles Bibliográficos
Autores principales: Imai, Hisao, Wasamoto, Satoshi, Tsuda, Takeshi, Nagai, Yoshiaki, Kishikawa, Takayuki, Masubuchi, Ken, Osaki, Takashi, Miura, Yosuke, Umeda, Yukihiro, Ono, Akihiro, Minemura, Hiroyuki, Yamada, Yutaka, Nakagawa, Junichi, Kozu, Yuki, Taniguchi, Hirokazu, Ohta, Hiromitsu, Kasai, Takashi, Kaira, Kyoichi, Kagamu, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481141/
https://www.ncbi.nlm.nih.gov/pubmed/37469246
http://dx.doi.org/10.1111/1759-7714.15036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481141/
https://www.ncbi.nlm.nih.gov/pubmed/37469246
http://dx.doi.org/10.1111/1759-7714.15036

Ejemplares similares